Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 30Other hematologic neoplasm 27Plasma cell 26Myeloid 8Sarcoma 6CNS 4Gastrointestinal 3Dermatologic 2Other solid neoplasm 1Head & Neck 1Gynecologic 1

Conditions

Pancreatic Neoplasms 3Ovarian Neoplasms 1Colorectal Neoplasms 1

Interventions

Oxaliplatin 1004Fluorouracil 800Capecitabine 764Gemcitabine 650Leucovorin 559Irinotecan 537Bevacizumab 513Radiotherapy 460Cisplatin 440Drug Therapy 298Cetuximab 280Surgical Procedures, Operative 229Paclitaxel 228S 1 (combination) 217pembrolizumab 205Docetaxel 199130-nm albumin-bound paclitaxel 196Nivolumab 193sintilimab 191Radiosurgery 190lenvatinib 180Folfox protocol 179Sorafenib 178Albumin-Bound Paclitaxel 173apatinib 170tislelizumab 161camrelizumab 160Neoadjuvant Therapy 158Blood Specimen Collection 154durvalumab 148

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × plerixafor × Gastrointestinal × Clear all
NCT04177810 2024-02-23

Plerixafor and Cemiplimab in Metastatic Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2 Completed
25 enrolled 9 charts
Gastrointestinal

Pancreatic Neoplasms

NCT03277209 2020-03-02

To Assess the Safety of Continuous IV Administration of Plerixafor and Assess Impact on the Immune Microenvironment in Patients With Pancreatic, Ovarian and Colorectal Adenocarcinomas

Weill Medical College of Cornell University

Phase 1 Terminated
2 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT02179970 2019-07-23

CAM-PLEX

Cambridge University Hospitals NHS Foundation Trust

Phase 1 Completed
26 enrolled
GastrointestinalGynecologic

Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡